Astragalin (Synonyms: Astragaline; 3-Glucosylkaempferol; Kaempferol 3-β-D-glucopyranoside)

Name: Astragalin
Brand: MedChemExpress
SKU: HY-N0015
Rating: 5.0 (17 reviews)

Cat. No.: HY-N0015 Purity: 99.94%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Astragalin (Astragaline) a flavonoid with anti-inflammatory, antioxidant, anticancer, bacteriostatic activity. Astragalin inhibits cancer cells proliferation and migration, induces apoptosis. Astragalin is orally active and provides nerve and heart protection, and resistance against and osteoporosis.

For research use only. We do not sell to patients.

CAS No. : 480-10-4

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 17 publication(s) in Google Scholar

Other Forms of Astragalin:

Astragalin (Standard) In-stock

17 Publications Citing Use of MCE Astragalin

Cell Proliferation/Viability Assay

Cell Imaging/Staining

Apoptosis Analysis

Histological Imaging/Staining

: Astragalin purchased from MedChemExpress. Usage Cited in: Bioresour Bioprocess. 2025 Dec 3;12(1):139. [Abstract]; CCK8 assay of Astragalin (1, 10, 20 μM) on AR42J cells.

: Astragalin purchased from MedChemExpress. Usage Cited in: Bioresour Bioprocess. 2025 Dec 3;12(1):139. [Abstract]; Live/dead staining showing living (green) and dying/dead (red) cells treated with Astragalin (10 μM).

: Astragalin purchased from MedChemExpress. Usage Cited in: Bioresour Bioprocess. 2025 Dec 3;12(1):139. [Abstract]; Apoptotic rate analyzed by Annexin V-FITC/PI staining and flow cytometry treated with Astragalin (10 μM).

: Astragalin purchased from MedChemExpress. Usage Cited in: Bioresour Bioprocess. 2025 Dec 3;12(1):139. [Abstract]; Images of H&E staining in pancreatic tissue treated with Astragalin (50, 75, 100 mg/kg, i.g.).

: Astragalin purchased from MedChemExpress. Usage Cited in: Bioresour Bioprocess. 2025 Dec 3;12(1):139. [Abstract]; Western blot of the NLRP3 signaling pathway treated with Astragalin (100 mg/kg, i.g.).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

p65

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 10 μM Compound: 6	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 28165740]
BT-549	IC₅₀	> 10 μM Compound: 6	Cytotoxicity against human BT549 cells after 48 hrs by SRB assay Cytotoxicity against human BT549 cells after 48 hrs by SRB assay	[PMID: 28165740]
BV-2	IC₅₀	23.5 μM Compound: 6	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay	[PMID: 28165740]
BV-2	IC₅₀	77.36 μM Compound: 13	Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method	[PMID: 23149227]
H9	EC₅₀	80 μg/mL Compound: 4	Inhibitory activity against HIV-1 IIIB replication in H9 cell line Inhibitory activity against HIV-1 IIIB replication in H9 cell line	10.1016/0960-894X(94)80015-4
H9	IC₅₀	< 100 μg/mL Compound: 4	Inhibitory activity against H9 cells uninfected with HIV-1 Inhibitory activity against H9 cells uninfected with HIV-1	10.1016/0960-894X(94)80015-4
HCT-15	IC₅₀	23.5 μM Compound: 11	Antiproliferative activity against human HCT15 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human HCT15 cells after 72 hrs by sulforhodamine B assay	[PMID: 25981689]
HL-60	IC₅₀	> 50 μg/mL Compound: 4	Antioxidant activity in human HL60 cells assessed as reduction of cytochrome-c release Antioxidant activity in human HL60 cells assessed as reduction of cytochrome-c release	[PMID: 10650074]
Jurkat	IC₅₀	> 100 μg/mL Compound: 9	Cytotoxicity against human Jurkat T cells after 36 hrs by MTT assay Cytotoxicity against human Jurkat T cells after 36 hrs by MTT assay	[PMID: 21546250]
MDCK	CC₅₀	143.3 μg/mL Compound: 8	Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 15104496]
MDCK	CC₅₀	392.5 μg/mL Compound: 8	Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 15104496]
MDCK	CC₅₀	> 300 μM Compound: 8	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 19729316]
MDCK	EC₅₀	40 μM Compound: 8	Antiviral activity against influenza A virus H1N1 A/PR/8/34 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against influenza A virus H1N1 A/PR/8/34 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect	[PMID: 19729316]
MDCK	EC₅₀	61.9 μM Compound: 8	Antiviral activity against influenza A virus H9N2 A/Chicken/Korea/MS96/96 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against influenza A virus H9N2 A/Chicken/Korea/MS96/96 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect	[PMID: 19729316]
MDCK	EC₅₀	72.8 μM Compound: 8	Inhibition of Influenza A virus A/PR/8/34 (H1N1) neuraminidase activity measured in infected MDCK cells using MUNANA as substrate assessed as fluorescence intensity after 48 hrs Inhibition of Influenza A virus A/PR/8/34 (H1N1) neuraminidase activity measured in infected MDCK cells using MUNANA as substrate assessed as fluorescence intensity after 48 hrs	[PMID: 25927664]
MDCK	IC₅₀	143.3 μg/mL Compound: 8	Cytotoxicity against MDCK cells Cytotoxicity against MDCK cells	[PMID: 15104496]
MDCK	IC₅₀	24.5 μg/mL Compound: 8	Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 15104496]
MDCK	IC₅₀	26.9 μg/mL Compound: 8	Antiviral activity against RSV Long in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against RSV Long in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 15104496]
MDCK	IC₅₀	35.8 μg/mL Compound: 8	Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 15104496]
P388	ED₅₀	8.2 μg/mL Compound: Astragalin	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 3404159]
RAW264.7	IC₅₀	37.1 μM Compound: 21	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by griess reaction analysis Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by griess reaction analysis	[PMID: 24679441]
RAW264.7	IC₅₀	40.6 μM Compound: 21	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs by sandwich ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs by sandwich ELISA	[PMID: 24679441]
RAW264.7	IC₅₀	64 μM Compound: 9	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method	[PMID: 21353543]
RAW264.7	IC₅₀	67.1 μM Compound: 9	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs	[PMID: 21353543]
SK-MEL-2	IC₅₀	> 10 μM Compound: 6	Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay	[PMID: 28165740]
SK-OV-3	IC₅₀	> 10 μM Compound: 6	Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 28165740]
SW-620	IC₅₀	4.6 μM Compound: 11	Antiproliferative activity against human SW620 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human SW620 cells after 72 hrs by sulforhodamine B assay	[PMID: 25981689]
U-251	IC₅₀	37.6 μM Compound: 11	Antiproliferative activity against human U251 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human U251 cells after 72 hrs by sulforhodamine B assay	[PMID: 25981689]
U-87MG ATCC	IC₅₀	3.12 μM Compound: 11	Antiproliferative activity against human U87MG cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human U87MG cells after 72 hrs by sulforhodamine B assay	[PMID: 25981689]
Vero	IC₅₀	174.3 μM Compound: 1	Cytotoxicity against african green monkey Vero cells assessed as cell viability after 72 hrs by FACS analysis Cytotoxicity against african green monkey Vero cells assessed as cell viability after 72 hrs by FACS analysis	[PMID: 21466157]

In Vitro

Astragalin (0-80 μg/mL; 24 h, 48 h, 72 h) inhibits cancer cells viability and migration at 20, 40, 80 μM, and shows no cytotoxicity to normal human colon epithelial cell lines NCM460^[1].
Astragalin (80 μg/mL; 4 h, 8 h) interrupts the NF-κB signaling pathway and inhibits NF-κB P65 transcriptional activity in HCT116 cells stimulated by TNF-α^[1].
Astragalin (20, 40, 80 μg/mL; 48 h) induces HCT116 cells apoptosis and arrests cell cycle at G0/G1 phase^[1].
Astragalin (20, 40, 80 μg/mL; 48 h) increases the level of apoptin in HCT116 and decreases the level of anti-apoptotic proteins in a dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	Human colon cancer cell lines (HCT116, LoVo, SW620, SW480, Caco2) and human colon epithelial cell lines NCM460
Concentration:	0, 5, 10, 20, 40, 80 μg/mL
Incubation Time:	24, 48, 72 hours
Result:	Inhibits cancer cells (LoVo, SW620, SW480, Caco2, HCT116) activity at 20, 40, 80 μM. Inhibited HCT116 cells with IC₅₀s of 121.845, 87.908, 18.883 μg/mL at 24, 48, 72 hours, respectively. Showed no cytotoxicity with NCM460 cells.

Cell Cycle Analysis^[1]

Cell Line:	Human colon cancer cell HCT116
Concentration:	0, 20, 40, 80 μg/mL
Incubation Time:	48 hours
Result:	Arrested cell cycle at G0/G1.

Western Blot Analysis^[1]

Cell Line:	Human colon cancer cell HCT116
Concentration:	80 μg/mL; pre-treated with 20 ng/mL TNF-α
Incubation Time:	4 or 8 hours
Result:	Increased the expression of pro-apoptotic proteins (caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, P53, and Bax) and decreased the expression of anti-apoptotic proteins (cleaved caspase-3 and Bcl-2) in a dose-dependent manner.

Cell Migration Assay ^[1]

Cell Line:	Human colon cancer cell HCT116
Concentration:	0, 20, 40, 80 μg/mL
Incubation Time:	24, 48, 72 hours
Result:	Reduced release of MMP-2 and MMP-9 enzymes. Inhibited cell migration with mobilities of 14.38, 13.44, and 5.29% with 20, 40, and 80 μg/mL concentrations, respectively.

In Vivo

Astragalin (25, 50, and 75 mg/kg; p.o.; once every two days; 25 d) reduces the tumor volumes, tumor weight and tumor formation rates and decreases expression of p-NFκB and p-iκκα in nude mouse model with human colon cancer^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male BALB/c nude mice (4-week-old) with HCT116 cells (s.c.)^[1]
Dosage:	0 mg/kg, 25 mg/kg, 50 mg/kg, 75 mg/kg
Administration:	Oral gavage; once every two days; for 25 days
Result:	Resulted tumor inhibition rates of 17.43%, 34.89% (p < 0.01), and 67.06% with 25 mg/kg, 50 mg/kg, 75 mg/kg dose administration. Showed no effect on mouse weight.

Molecular Weight

448.38

Formula

C₂₁H₂₀O₁₁

CAS No.

480-10-4

Appearance

Solid

Color

Light yellow to yellow

SMILES

OC1=CC2=C(C(C(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)=C(C4=CC=C(O)C=C4)O2)=O)C(O)=C1

Structure Classification

Initial Source

Microorganisms

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (223.03 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2303 mL	11.1513 mL	22.3025 mL
5 mM	0.4461 mL	2.2303 mL	4.4605 mL
10 mM	0.2230 mL	1.1151 mL	2.2303 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 1% CMC-Na/saline water
Solubility: 10 mg/mL (22.30 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.94%

Select Batch:

Data Sheet (284 KB) SDS (394 KB)

COA (255 KB) LCMS (89 KB)

Handling Instructions (2659 KB)

References

[1]. Yang M, et al. Astragalin Inhibits the Proliferation and Migration of Human Colon Cancer HCT116 Cells by Regulating the NF-κB Signaling Pathway. Front Pharmacol. 2021 Apr 19;12:639256. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.2303 mL	11.1513 mL	22.3025 mL	55.7563 mL
	5 mM	0.4461 mL	2.2303 mL	4.4605 mL	11.1513 mL
	10 mM	0.2230 mL	1.1151 mL	2.2303 mL	5.5756 mL
	15 mM	0.1487 mL	0.7434 mL	1.4868 mL	3.7171 mL
	20 mM	0.1115 mL	0.5576 mL	1.1151 mL	2.7878 mL
	25 mM	0.0892 mL	0.4461 mL	0.8921 mL	2.2303 mL
	30 mM	0.0743 mL	0.3717 mL	0.7434 mL	1.8585 mL
	40 mM	0.0558 mL	0.2788 mL	0.5576 mL	1.3939 mL
	50 mM	0.0446 mL	0.2230 mL	0.4461 mL	1.1151 mL
	60 mM	0.0372 mL	0.1859 mL	0.3717 mL	0.9293 mL
	80 mM	0.0279 mL	0.1394 mL	0.2788 mL	0.6970 mL
	100 mM	0.0223 mL	0.1115 mL	0.2230 mL	0.5576 mL

Astragalin Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Astragalin480-10-4Astragaline 3-Glucosylkaempferol Kaempferol 3-β-D-glucopyranosideApoptosisNF-κBNuclear factor-κBNuclear factor-kappaB3-O-glucoside of kaempferolanti-inflammatoryantioxidantanticancerbacteriostaticproliferationmigrationInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Astragalin (Synonyms: Astragaline; 3-Glucosylkaempferol; Kaempferol 3-β-D-glucopyranoside)

Customer Review

Other Forms of Astragalin:

Astragalin Related Antibodies

17 Publications Citing Use of MCE Astragalin

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Astragalin Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Astragalin Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report